Micro-X Toekomstige groei

Future criteriumcontroles 6/6

Micro-X zal naar verwachting groeien in winst en omzet met respectievelijk 68.6% en 38.2% per jaar. De winst per aandeel zal naar verwachting groeien met 71.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 46.7% zijn.

Belangrijke informatie

68.6%

Groei van de winst

71.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	16.2%
Inkomstengroei	38.2%
Toekomstig rendement op eigen vermogen	46.7%
Dekking van analisten	Low
Laatst bijgewerkt	03 Nov 2024

Recente toekomstige groei-updates

Recent updates

Slammed 27% Micro-X Limited (ASX:MX1) Screens Well Here But There Might Be A Catch

Sep 20

Shareholders May Not Be So Generous With Micro-X Limited's (ASX:MX1) CEO Compensation And Here's Why

Nov 07

We Think Micro-X (ASX:MX1) Needs To Drive Business Growth Carefully

Jul 07

Here's Why We're Watching Micro-X's (ASX:MX1) Cash Burn Situation

Mar 01

What We Learned About Micro-X's (ASX:MX1) CEO Pay

Jan 29

What Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?

Jan 08

Have Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?

Dec 18

Micro-X Limited's (ASX:MX1) Shift From Loss To Profit

Nov 27

Winst- en omzetgroeiprognoses

ASX:MX1 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	52	4	N/A	2	1
6/30/2026	37	-5	N/A	-6	1
6/30/2025	25	-7	N/A	0	1
6/30/2024	15	-10	-7	-6	N/A
3/31/2024	15	-12	-6	-6	N/A
12/31/2023	15	-15	-5	-5	N/A
9/30/2023	15	-13	-9	-8	N/A
6/30/2023	15	-11	-12	-11	N/A
3/31/2023	15	-11	-14	-13	N/A
12/31/2022	15	-12	-15	-14	N/A
9/30/2022	12	-15	-17	-16	N/A
6/30/2022	9	-17	-19	-18	N/A
3/31/2022	6	-18	-18	-16	N/A
12/31/2021	4	-19	-16	-15	N/A
9/30/2021	4	-17	-13	-12	N/A
6/30/2021	4	-15	-11	-10	N/A
3/31/2021	5	-13	-12	-11	N/A
12/31/2020	6	-11	-13	-12	N/A
9/30/2020	5	-10	-12	-11	N/A
6/30/2020	4	-10	-12	-9	N/A
3/31/2020	3	-9	-11	-8	N/A
12/31/2019	2	-8	-10	-7	N/A
9/30/2019	2	-9	-9	-7	N/A
6/30/2019	2	-10	-9	-7	N/A
3/31/2019	2	-14	-9	-8	N/A
12/31/2018	2	-18	-10	-9	N/A
9/30/2018	2	-17	-9	-8	N/A
6/30/2018	2	-17	-8	-8	N/A
3/31/2018	1	-14	N/A	-9	N/A
12/31/2017	1	-11	N/A	-11	N/A
9/30/2017	1	-12	N/A	-11	N/A
6/30/2017	1	-13	N/A	-11	N/A
3/31/2017	1	-13	N/A	-10	N/A
12/31/2016	1	-13	N/A	-9	N/A
9/30/2016	1	-12	N/A	-11	N/A
6/30/2016	1	-11	N/A	-13	N/A
3/31/2016	1	-12	N/A	-10	N/A
12/31/2015	0	-13	N/A	-8	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-10	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat MX1 de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat MX1 de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat MX1 binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van MX1 ( 38.2% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.7% per jaar).

Hoge groei-inkomsten: De omzet van MX1 ( 38.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MX1 zal naar verwachting over 3 jaar zeer hoog zijn ( 46.7 %).

Micro-X Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 14%

Forecast to breakeven in 2027

Consensus revenue estimates fall by 20%

Price target decreased by 11% to AU$0.25

Forecast breakeven date pushed back to 2025

Consensus forecasts updated

Recent updates

Less than half of directors are independent

Consensus revenue estimates decrease by 14%

Micro-X Limited, Annual General Meeting, Nov 12, 2024

Slammed 27% Micro-X Limited (ASX:MX1) Screens Well Here But There Might Be A Catch

Full year 2024 earnings: Revenues miss analyst expectations

Forecast to breakeven in 2027

Take Care Before Diving Into The Deep End On Micro-X Limited (ASX:MX1)

Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million.

New minor risk - Shareholder dilution

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

New minor risk - Share price stability

Micro-X Limited (ASX:MX1) Doing What It Can To Lift Shares

Micro-X Reveals First Look At New Mobile Stroke Diagnosis Device

Consensus revenue estimates fall by 20%

Price target decreased by 11% to AU$0.25

New minor risk - Profitability

Micro-X Limited, Annual General Meeting, Nov 16, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Non-Executive Director exercised options to buy AU$174k worth of stock.

Sentiment Still Eluding Micro-X Limited (ASX:MX1)

Forecast breakeven date pushed back to 2025

Is Micro-X (ASX:MX1) In A Good Position To Invest In Growth?

First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.019 loss in 1H 2022)

Less than half of directors are independent

Micro-X Limited announced that it has received AUD 7.454223 million in funding from Varex Imaging Corporation

Less than half of directors are independent

Shareholders May Not Be So Generous With Micro-X Limited's (ASX:MX1) CEO Compensation And Here's Why

Consensus forecasts updated

Less than half of directors are independent

Micro-X Limited, Annual General Meeting, Nov 14, 2022

Micro-X Limited Announces Resignation of Yasmin King as Director

Micro-X Limited announced that it expects to receive AUD 7.454223 million in funding from Varex Imaging Corporation

Micro-X Limited Launches Next Generation Micro-X Rover, the Rover Plus

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to AU$0.36

We Think Micro-X (ASX:MX1) Needs To Drive Business Growth Carefully

Price target decreased to AU$0.51

Micro-X Ltd Appoints Ilona Meyer to Its Board as A Non-Executive Director and Member of the Micro-X Audit & Risk Committee, Effective 7Th March 2022

Here's Why We're Watching Micro-X's (ASX:MX1) Cash Burn Situation

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Full year 2021 earnings released: AU$0.037 loss per share (vs AU$0.043 loss in FY 2020)

Consensus revenue estimates fall to AU$4.20m

Micro-X Ltd Launches New Version of the Rover Mobile DR for Use in Small-Animal Veterinary Hospitals

Micro-X Limited Announces Rover FDA Approval Opens US Healthcare Market

Consensus forecasts updated

Analysts update estimates

First half 2021 earnings released: AU$0.013 loss per share (vs AU$0.025 loss in 1H 2020)

New 90-day high: AU$0.40

Micro-X Limited announced that it expects to receive AUD 30.5 million in funding

What We Learned About Micro-X's (ASX:MX1) CEO Pay

What Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?

New 90-day high: AU$0.39

Micro-X Limited Signs $1.3 Million Rover Contract for Australian Defence Force

Have Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?

Micro-X Limited Announces Rejoining of Jim McDowell as Non-Executive Director from January 1, 2021

New 90-day high: AU$0.36

Micro-X Limited's (ASX:MX1) Shift From Loss To Profit

Price target raised to AU$0.50

Micro-X Limited Amends Nano Distribution Agreement with Carestream Health Inc

Micro-X Ltd Announces Management Changes

New 90-day high: AU$0.26

Analysts update estimates

Micro-X Limited Signs $1.4 Million Contract for Rover Launches Micro-X Second Product

New 90-day high: AU$0.21

Micro-X Limited Auditor Raises 'Going Concern' Doubt